PT831821E - (-)norcisaprida opticamente pura para o tratamento de desordens do tracto digestivo - Google Patents
(-)norcisaprida opticamente pura para o tratamento de desordens do tracto digestivoInfo
- Publication number
- PT831821E PT831821E PT96915877T PT96915877T PT831821E PT 831821 E PT831821 E PT 831821E PT 96915877 T PT96915877 T PT 96915877T PT 96915877 T PT96915877 T PT 96915877T PT 831821 E PT831821 E PT 831821E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- optically pure
- norcisaprida
- digestive tract
- tract disorders
- Prior art date
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 title 1
- 230000002411 adverse Effects 0.000 abstract 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 abstract 2
- 229960005132 cisapride Drugs 0.000 abstract 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 abstract 2
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/485,570 US5712293A (en) | 1995-06-07 | 1995-06-07 | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
Publications (1)
Publication Number | Publication Date |
---|---|
PT831821E true PT831821E (pt) | 2004-11-30 |
Family
ID=23928664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT96915877T PT831821E (pt) | 1995-06-07 | 1996-05-17 | (-)norcisaprida opticamente pura para o tratamento de desordens do tracto digestivo |
Country Status (11)
Country | Link |
---|---|
US (4) | US5712293A (pt) |
EP (2) | EP0831821B1 (pt) |
JP (1) | JPH11510477A (pt) |
AT (2) | ATE352304T1 (pt) |
AU (1) | AU720407B2 (pt) |
CA (1) | CA2224005A1 (pt) |
DE (2) | DE69633016T2 (pt) |
DK (1) | DK0831821T3 (pt) |
ES (2) | ES2222480T3 (pt) |
PT (1) | PT831821E (pt) |
WO (1) | WO1996040133A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
AU780107B2 (en) * | 1996-07-19 | 2005-03-03 | Sepracor, Inc. | Methods for treating emesis and central nervous system disorders using optically pure () norcisapride |
US6147093A (en) | 1996-07-19 | 2000-11-14 | Sepracor Inc. | Methods for treating gastroesophageal reflux disease |
US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
ES2180032T3 (es) * | 1996-10-15 | 2003-02-01 | Janssen Pharmaceutica Nv | Procedimiento para preparar un compuesto intermedio util en la sintesis de cisaprida. |
KR100358374B1 (ko) * | 1997-07-11 | 2002-10-25 | 얀센 파마슈티카 엔.브이. | 5-ht3 및 5-ht4 매개된 질환에 유용한(+)-노르시사프라이드 |
CZ20004736A3 (cs) | 1998-06-15 | 2001-09-12 | Sepracor, Inc. | Farmaceutický prostředek |
EP1464333A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
US6362202B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US7678390B2 (en) * | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
WO2003000114A2 (en) * | 2001-06-21 | 2003-01-03 | Beth Israel Deaconess Medical Center | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US7482365B2 (en) * | 2002-02-08 | 2009-01-27 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases |
AU2003211102B2 (en) * | 2002-02-13 | 2010-03-04 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating vascular disease |
CA2481786A1 (en) * | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
RS91004A (en) * | 2002-04-15 | 2007-02-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education, | Methods of treating ileus |
US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
WO2003096977A2 (en) * | 2002-05-17 | 2003-11-27 | Yale University | Methods of treating hepatitis |
EA200401622A1 (ru) * | 2002-06-05 | 2005-06-30 | Йейл Юниверсити | Способы лечения ангиогенеза, роста опухолей и метастазов |
US20040131703A1 (en) * | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
JP2006514621A (ja) * | 2002-11-07 | 2006-05-11 | ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 出血性ショックの治療 |
US8524736B2 (en) | 2004-01-07 | 2013-09-03 | Armetheon, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
US8138204B2 (en) * | 2004-01-07 | 2012-03-20 | Aryx Therapeutics, Inc. | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
DK2194053T3 (da) | 2004-01-07 | 2013-07-01 | Armetheon Inc | Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet. |
AU2006284601B2 (en) * | 2005-08-31 | 2012-12-20 | Renexxion, Llc | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders |
US20080085915A1 (en) * | 2006-06-23 | 2008-04-10 | Cyrus Becker | Compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639002A (en) * | 1970-04-06 | 1972-02-01 | Gulf & Western Metals Forming | Seat construction |
US5057525A (en) * | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
CA1183847A (en) * | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US4962115A (en) * | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US5137896A (en) * | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
WO1994001112A1 (en) * | 1992-07-07 | 1994-01-20 | Sepracor Inc. | Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
JPH08502031A (ja) * | 1992-07-07 | 1996-03-05 | セプラコア インコーポレーテッド | 胃食道逆流疾患およびその他の障害を治療するために▲(+)▼シサプリドを使用する方法 |
JPH08512322A (ja) * | 1993-07-06 | 1996-12-24 | メルク エンド カンパニー インコーポレーテッド | H▲下2▼拮抗剤−胃腸運動性の薬剤組合せ物 |
US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
-
1995
- 1995-06-07 US US08/485,570 patent/US5712293A/en not_active Expired - Fee Related
-
1996
- 1996-05-17 AT AT04015312T patent/ATE352304T1/de not_active IP Right Cessation
- 1996-05-17 DE DE69633016T patent/DE69633016T2/de not_active Expired - Fee Related
- 1996-05-17 EP EP96915877A patent/EP0831821B1/en not_active Expired - Lifetime
- 1996-05-17 JP JP9500602A patent/JPH11510477A/ja not_active Ceased
- 1996-05-17 AT AT96915877T patent/ATE271870T1/de not_active IP Right Cessation
- 1996-05-17 ES ES96915877T patent/ES2222480T3/es not_active Expired - Lifetime
- 1996-05-17 DK DK96915877T patent/DK0831821T3/da active
- 1996-05-17 AU AU57533/96A patent/AU720407B2/en not_active Ceased
- 1996-05-17 PT PT96915877T patent/PT831821E/pt unknown
- 1996-05-17 EP EP04015312A patent/EP1462104B1/en not_active Expired - Lifetime
- 1996-05-17 ES ES04015312T patent/ES2276194T3/es not_active Expired - Lifetime
- 1996-05-17 CA CA002224005A patent/CA2224005A1/en not_active Abandoned
- 1996-05-17 DE DE69636877T patent/DE69636877T2/de not_active Expired - Fee Related
- 1996-05-17 WO PCT/US1996/007159 patent/WO1996040133A1/en active IP Right Grant
-
1997
- 1997-09-19 US US08/933,953 patent/US5877189A/en not_active Expired - Fee Related
-
1998
- 1998-10-13 US US09/170,741 patent/US6156770A/en not_active Expired - Fee Related
-
2000
- 2000-10-23 US US09/693,945 patent/US6313144B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69633016T2 (de) | 2004-12-23 |
DE69633016D1 (de) | 2004-09-02 |
EP1462104A1 (en) | 2004-09-29 |
US5877189A (en) | 1999-03-02 |
AU5753396A (en) | 1996-12-30 |
US6313144B1 (en) | 2001-11-06 |
ES2276194T3 (es) | 2007-06-16 |
US6156770A (en) | 2000-12-05 |
DK0831821T3 (da) | 2004-11-22 |
CA2224005A1 (en) | 1996-12-19 |
DE69636877D1 (de) | 2007-03-15 |
ATE271870T1 (de) | 2004-08-15 |
DE69636877T2 (de) | 2007-05-31 |
ES2222480T3 (es) | 2005-02-01 |
EP0831821B1 (en) | 2004-07-28 |
AU720407B2 (en) | 2000-06-01 |
JPH11510477A (ja) | 1999-09-14 |
ATE352304T1 (de) | 2007-02-15 |
EP0831821A1 (en) | 1998-04-01 |
US5712293A (en) | 1998-01-27 |
EP1462104B1 (en) | 2007-01-24 |
WO1996040133A1 (en) | 1996-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT831821E (pt) | (-)norcisaprida opticamente pura para o tratamento de desordens do tracto digestivo | |
NO950263L (no) | Optisk rene salter av pyridinylmetylsulfinyl-1H-benzimidazolforbindelser | |
DK1574209T3 (da) | Fremgangsmåde til behandling af ophthalmiske sygdomme | |
FI973163A (fi) | Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä | |
FI915656A0 (fi) | Terapeutiskt anvaendbara 2-aminotetralin derivat. | |
DK0659410T3 (da) | Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger | |
ATE251139T1 (de) | (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten | |
NO20041166L (no) | Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament | |
DK0966277T3 (da) | Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom | |
NO985299D0 (no) | Preparat av prostaglandin I-derivat med langsom frigj°ring | |
ATE406887T1 (de) | R-bambuterol, seine herstellung und therapeutische verwendungen | |
ES2180575T3 (es) | Pirido(2,3-b)(1,4)benzodiazepinonas como ligando de receptor m2 para el tratamiento de trastornos neurologicos. | |
PT91006A (pt) | Processo para a preparacao de um novo sal de estroncio | |
DK0617959T3 (da) | Lægemiddel til behandling af hudsygdomme | |
DK0814791T3 (da) | Aminotetralin-derivat til behandlingen af cardiovaskulære sygdomme | |
NO990450D0 (no) | Behandling av sinnslidelser | |
DK544689D0 (da) | Terapeutisk aktive forbindelser | |
ATE236634T1 (de) | Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen | |
FI103970B1 (fi) | Menetelmä kivun lievittämiseen sekä ihotautien ja muistin toimintahäiriöiden hoitoon tarkoitettujen 3-(1,2-bentsisoksatsol-3-yyli)-4-pyridiiniamiinien ja näiden johdannaisten valmistamiseksi | |
PT889044E (pt) | Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central | |
EP0661974A4 (en) | METHODS AND COMPOSITIONS FOR TREATING INFECTIONS USING OPTICALLY PURE (R) -LOMEFLOXACIN. | |
ES2140925T3 (es) | Procedimiento para la racemizacion de aminas opticamente activas. |